← Leaderboards
Yiping He
Duke University
$2,223,963
Attributed
$2,223,963
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $499.4K · FY2017–25$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,223,963 · 2
By mechanism
R01$2,223,963 · 2
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Jiaoti Huang$7,876,254
- Charles Michael Cotten$5,917,623
- Michael Kay Reedy$7,544,905
- Aravind Asokan$26,081,479
- Salvatore V Pizzo$13,358,085
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseGenesResistanceCellsIn VivoIn VitroMalignant NeoplasmsProteinsTargeted TreatmentGenetic TranscriptionMolecularMediatingCancer CellGene ExpressionBypassClinically SignificantAdenineFrequenciesCellular Metabolic ProcessEpidermal Growth Factor ReceptorCell LineAffectBiological Adaptation To StressEpigenetic Process
Grant awards (6)
Targeting MED31-driven transcription recycling in lethal prostate cancer$499,449
R01 · FY2025 · CA · contact PI
Exploiting MTAP deletion for GBM therapeutics$344,749
R01 · FY2021 · NS · contact PI
Exploiting MTAP deletion for GBM therapeutics$344,809
R01 · FY2020 · NS · contact PI
Exploiting MTAP deletion for GBM therapeutics$344,868
R01 · FY2019 · NS · contact PI
Exploiting MTAP deletion for GBM therapeutics$344,982
R01 · FY2018 · NS · contact PI
Exploiting MTAP deletion for GBM therapeutics$345,106
R01 · FY2017 · NS · contact PI